Compare Devon Energy Corp (DVN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Incyte Corporation — how do they compare? Devon Energy Corp trades at $44.89 (market cap $49.94B), while Incyte Corporation trades at $120.8 (market cap $24.54B). The key difference: Devon Energy Corp is far larger — about 2× Incyte Corporation's market cap, and Devon Energy Corp pays a 2.82% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DVN | INCY | |
|---|---|---|
Market Cap | $49.94B | $24.54B |
Sector | Energy | Health |
52-Week High | $52.07 | $129.93 |
52-Week Low | $31.74 | $81.61 |
Enterprise Value | $60.68B | $20.04B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $44.9, down 1.01% today, with a bullish technical signal and strong Q2 2026 earnings beat. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil prices. Valuation remains attractive with a P/E of 9.87 and P/S of 1.62. Recent news highlights a 33% dividend increase and $1.25 billion debt repayment, reinforcing financial health.
The outlook is positive given robust free cash flow, debt reduction targets, and analyst consensus price target of $61.91 implying 38% upside. Key risks include oil price volatility and integration challenges from the Coterra merger. Institutional sentiment is strongly bullish with 71% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
